Twist Bioscience Synthetic SARS-CoV-2 RNA Controls Added to FDA Website as Reference Materials

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its synthetic SARS-CoV-2 RNA Controls to provide quality control for the development, verification, and ongoing validation for diagnostic tests are now included on the U.S. Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2. “We are worki

Click to view original post